Pekka Taimen profile picture
Professor, Institute of Biomedicine
InFLAMES Flagship


+358 29 450 4524
+358 50 431 1353
Kiinamyllynkatu 10

Areas of expertise

cell biology
prostate cancer, bladder cancer, cardiomyopathy, nuclear lamin


Pekka Taimen received his MD degree from the University of Turku in 2001 and defended his thesis at the Department of Pathology, University of Turku in 2004. In 2008-2009 PT worked as a postdoctoral fellow in the laboratory of Prof. Robert D. Goldman, Northwestern University Medical School, Chicago. Postdoctoral studies focusing on nuclear intermediate filament proteins called lamins were further continued as a junior group leader after returning back to Turku in early 2010. In 2011 PT received a specialist degree in Pathology and since then he has worked as a part-time specialist at the Pathology Division, Turku University Hospital with special focus on uropathology. From 2012 PT has worked as a Clinical lecturer in Pathology and between 2015-2019 as a part-time Academy of Finland Clinical Researcher. PT was appointed as a tenure track Assistant Professor of Molecular Pathology in January 2019 and an Associate Professor in August 2020. In January 2022, PT was appointed as a Professor of Molecular Pathology and he currently serves as the head of the pathology unit at the Faculty of Medicine, University of Turku.


Pekka Taimen has more than 10 years of experience in teaching medical students at the Institute of Biomedicine, University of Turku. He has served first as a university teacher and from 2012 as a clinical lecturer. In 2015 PT received the Lecturer of the Year award in the Faculty of Medicine.


Professor Pekka Taimen has 20 years of experience in cell and molecular biology as well as in translational research. The main focus of his research group is on human diseases caused by lamin mutations, such as cardiomyopathies and premature aging syndrome. More recently, PT has also actively worked on prostate and bladder cancer related projects including novel biomarkers, biobanking, patient derived cell lines and improved imaging techniques utilizing digital pathology and machine learning approaches.


Sort by:

STAT5b is a key effector of NRG-1/ERBB4-mediated myocardial growth (2023)

EMBO Reports
Vaparanta Katri, Jokilammi Anne, Paatero Ilkka, Merilahti Johannes A, Heliste Juho, Hemanthakumar Karthik Amudhala, Kivelä Riikka, Alitalo Kari, Taimen Pekka, Elenius Klaus
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) (2022)

BMJ Open
Ettala Otto, Jambor Ivan, Perez Ileana Montoya, Seppänen Marjo, Kaipia Antti, Seikkula Heikki, Syvänen Kari T, Taimen Pekka, Verho Janne, Steiner Aida, Saunavaara Jani, Saukko Ekaterina, Löyttyniemi Eliisa, Sjoberg Daniel D, Vickers Andrew, Aronen Hannu, Boström Peter
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score (2022)

European Urology
Peters M., Eldred-Evans D., Kurver P., Falagario U.G., Connor M.J., Shah T.T., Verhoeff J.J.C., Taimen P., Aronen H.J., Knaapila J., Montoya Perez I., Ettala O., Stabile A., Gandaglia G., Fossati N., Martini A., Cucchiara V., Briganti A., Lantz A., Picker W., Haug E.S., Nordström T., Tanaka M.B., Reddy D., Bass E., van Rossum P.S.N., Wong K., Tam H., Winkler M., Gordon S., Qazi H., Boström P.J., Jambor I., Ahmed H.U.
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))